Kerstin Kapp

Translational R&D
Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors.

Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors.

Journal: Oncoimmunology

Published: June 21, 2019

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study.

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 24, 2018

EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy.

EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: August 23, 2018

Distinct immunological activation profiles of dSLIM® and ProMune® depend on their different structural context.

Distinct immunological activation profiles of dSLIM® and ProMune® depend on their different structural context.

Journal: Immunity, inflammation and disease

Published: February 12, 2016

Targeting of the WT191-138 fragment to human dendritic cells improves leukemia-specific T-cell responses providing an alternative approach to WT1-based vaccination.

Targeting of the WT191-138 fragment to human dendritic cells improves leukemia-specific T-cell responses providing an alternative approach to WT1-based vaccination.

Journal: Cancer immunology, immunotherapy : CII

Published: November 13, 2015

Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist.

Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist.

Journal: Molecular therapy oncolytics

Published: August 14, 2015

Cationic lipid-formulated DNA vaccine against hepatitis B virus: immunogenicity of MIDGE-Th1 vectors encoding small and large surface antigen in comparison to a licensed protein vaccine.

Cationic lipid-formulated DNA vaccine against hepatitis B virus: immunogenicity of MIDGE-Th1 vectors encoding small and large surface antigen in comparison to a licensed protein vaccine.

Journal: PloS one

Published: February 14, 2014

Genuine Immunomodulation With dSLIM.

Genuine Immunomodulation With dSLIM.

Journal: Molecular therapy. Nucleic acids

Published: February 04, 2014

Dendritic cells from human mesenteric lymph nodes in inflammatory and non-inflammatory bowel diseases: subsets and function of plasmacytoid dendritic cells.

Dendritic cells from human mesenteric lymph nodes in inflammatory and non-inflammatory bowel diseases: subsets and function of plasmacytoid dendritic cells.

Journal: Immunology

Published: July 05, 2012

Stimulating surface molecules, Th1-polarizing cytokines, proven trafficking--a new protocol for the generation of clinical-grade dendritic cells.

Stimulating surface molecules, Th1-polarizing cytokines, proven trafficking--a new protocol for the generation of clinical-grade dendritic cells.

Journal: Cytotherapy

Published: July 04, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026